## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.7% below STRENGTH zone (3.0-6.0%); PEG 2.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($82.14)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Ex-Dividend Reminder: GE HealthCare Technologies, Toronto Dominion Bank and BankUnited**
- Source: Nasdaq | 20260107T151341 | Neutral | Relevance: 100%
- GE HealthCare Technologies (GEHC), Toronto Dominion Bank (TD), and BankUnited Inc. (BKU) are set to trade ex-dividend on January 9, 2026. This article details their upcoming quarterly dividends and the expected price adjustments for each stock based on these dividends. It also provides historical dividend charts and estimated annualized yields for these companies.

**2. Why GE HealthCare is warning investors about this share offer**
- Source: Stock Titan | 20260106T220631 | Somewhat-Bearish | Relevance: 100%
- GE HealthCare is urging its shareholders to reject an unsolicited "mini-tender" offer from Potemkin Limited, citing a significantly-below-market price of $54.20 per share compared to GEHC's $83.09 closing price. The company warns that mini-tender offers typically lack the full disclosure and procedural protections of larger tender offers and advises investors to exercise caution. GE HealthCare is not affiliated with Potemkin Limited and recommends shareholders consult with financial advisors.

**3. GEHC - GE HealthCare to announce fourth quarter and full year 2025 results on February 4, 2026**
- Source: ADVFN | 20260106T070846 | Neutral | Relevance: 100%
- GE HealthCare (Nasdaq: GEHC) announced it will release its fourth quarter and full year 2025 financial results before the market opens on Wednesday, February 4, 2026. The management team will also host a conference call and webcast on the same day at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time. The earnings release, financial information, and webcast replay will be available on the GE HealthCare Investor Relations website.

**4. GE HealthCare to announce fourth quarter and full year 2025 results on February 4, 2026**
- Source: sharewise.com | 20260105T160823 | Neutral | Relevance: 100%
- GE HealthCare (Nasdaq: GEHC) is scheduled to announce its fourth-quarter and full-year 2025 financial results on Wednesday, February 4, 2026, before the market opens. Management will host a conference call and webcast on the same day at 8:30 a.m. Eastern Time to discuss the results. The earnings release and webcast replay will be accessible via the GE HealthCare Investor Relations website.

**5. GE HealthCare to announce fourth quarter and full year 2025 results on February 4, 2026**
- Source: www.sharewise.com | 20260105T153759 | Neutral | Relevance: 100%
- GE HealthCare (NASDAQ: GEHC) announced it will release its fourth quarter and full year 2025 financial results on Wednesday, February 4, 2026, before market open. Management will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss the results. The company, a global healthcare solutions provider with approximately 53,000 colleagues, was recognized among Fortune's 2025 Worldâ€™s Most Admired Companies.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-07 | Stifel | $95 | $90 | +6% |
| 2026-01-05 | B of A Securiti | $92 | $82 | +12% |
| 2025-12-11 | Citigroup | $88 | $83 | +6% |
| 2025-12-11 | Jefferies | $105 | $95 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-07 | Stifel | main | Buy |
| 2026-01-05 | B of A Securiti | main | Neutral |
| 2025-12-11 | Citigroup | main | Neutral |
| 2025-12-11 | Jefferies | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 4 raises (avg +9%) could attract flows.
- Momentum building: MRS_10 improving +2.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.46 elevated, pricing in significant growth expectations. Forward P/E 17.4x stretched relative to 8% growth. Quality metrics strong (ROE 24%). Analyst sentiment positive (4 raises, avg +9%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $39.2B |
| Beta | 1.23 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.46 |
| Forward P/E | 17.4 |
| Current P/E | 18.8 |
| YoY Growth | 8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.9% to 1.7% (+2.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.3pp (needs >3.0% for momentum thesis). MRS_5 at 0.7% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.69% (CS: 70) | Neutral |
| RSI_14 | 61.5 | Neutral |
| MACD Histogram | 0.01 | Bullish |
| vs SMA20 | 1.024x | Above |
| vs SMA50 | 1.078x | Above |
| vs SMA200 | 1.151x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $85.76
- **Stop Loss:** $82.14 (4.2% risk)
- **Target:** $89.38 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 331
- **Position Value:** $28,386.56
- **Portfolio %:** 28.39%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk appetite. VIX at 15.38 sits in the normal range (18th percentile of 52-week) with modest upward drift, while yield curve remains positively sloped (+62bps 10Y-3M) supporting risk assets. Breadth at 59.5% shows healthy participation, though elevated put/call ratio (1.12) suggests some hedging activity. FOMC 20 days out provides runway for current conditions to persist.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-08 08:02 | MRS_10*